Vical Incorporated (Nasdaq: VICL) announced the initiation of its Phase 1/2 trial of the company's Vaxfectin™-formulated therapeutic vaccine for herpes ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE